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Abstract: Understanding complex diseases such as sporadic Alzheimer disease (AD) has been a major challenge. Unlike 
the familial forms of AD, the genetic and environmental risks factors identified for sporadic AD are extensive. MicroR-
NAs are one of the major noncoding RNAs that function as negative regulators to silence or suppress gene expression via 
translational inhibition or message degradation. Their discovery has evoked great excitement in biomedical research for 
their promise as potential disease biomarkers and therapeutic targets. Key microRNAs have been identified as essential 
for a variety of cellular events including cell lineage determination, proliferation, apoptosis, DNA repair, and cytoskeletal 
organization; most, if not all, acting to fine-tune gene expression at the post-transcriptional level in a host of cellular sig-
naling networks. Dysfunctional microRNA-mediated regulation has been implicated in the pathogenesis of many disease 
states. Here, the current understanding of the role of miRNAs in the central nervous system is reviewed with emphasis on 
their impact on the etiopathogenesis of sporadic AD. 
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INTRODUCTION 
1. The Pathology and Epidemiology of Alzheimer Disease 
  Alzheimer disease (AD) is an aging-associated dement-
ing disorder characterized by progressive neuronal degenera-
tion, gliosis, and the accumulation of extracellular deposits 
of amyloid (senile plaques; SP) and intracellular inclusions 
(neurofibrillary tangles; NFT) in discrete regions of the basal 
forebrain, hippocampus, and association cortices [1, 2]. Rare 
early-onset familial forms of AD with an inheritable autoso-
mal dominant mutation in either amyloid precursor protein 
(APP), presenilin-1 (PSEN1) or presenilin-2 (PSEN2) genes, 
account for <1% of AD cases. An unknown proportion of 
late-onset familial AD harbors “less aggressive” familial 
autosomal dominant mutations [3, 4]. The vast majority of 
AD cases are sporadic, with complex genetic, environmental 
and epigenetic risk factors [3, 5-7]. 
  Susceptible genetic polymorphisms in over 500 genes 
have been proposed as risk alleles [8], but only the apolipo-
protein E (APOE) 4 allele has been validated [9-11]. In 
these subgroups, the APOE4 allele acting with other genetic 
polymorphisms accelerates disease onset. There thus appear 
to exist multiple etiopathogenetic pathways which culminate  
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in a common histopathological profile characteristic of spo-
radic AD. A sub-classification taking into account AD fam-
ily history, age of onset, ethnicity, risk factors (i.e. educa-
tion, lifestyle, vascular pathology) and possibly gender could 
facilitate the delineation of discrete at-risk genetic networks 
associated with AD. 
  Definitive AD diagnosis is established by the postmortem 
quantification of SP and NFT in affected brain regions. The 
amyloid and neuritic plaques arise from the accumulation of 
1-40 and 1-42 amyloid beta (A) peptide residues following 
the sequential cleavage of the APP protein by -secretase (-
site APP cleaving enzyme 1, BACE1) and -secretase com-
plex (PSEN1 and PSEN2) [12]. Increases in A42 oligomers 
are believed to contribute to synaptic failure, oxidative stress 
and NFT [13]. NFT are filaments composed of a hyperphos-
phorylated microtubule-associated protein, tau [14]. 
  The increases in A and SP as well as NFT in the brain 
are aging-related phenomena and occur in the brains of the 
non-demented elderly. In familial AD, the ratio of A42/A40 
specifically increases [15]. However, mutations in the prese-
nilins and APP genes may also alter their signaling [16, 17] 
or transactivation functions [18, 19]. In sporadic AD, differ-
ent mechanisms which alter either A production or clear-
ance have been identified. For example, increases in BACE1 
expression and protein in AD brains correlate with higher A 
production [20]. Alternatively, APP cleavage by cathepsin B 
followed by glutaminyl cyclase modification of the truncated 
A (3–42) into pyroglutamate (pE)-modified A3(pE)–42 may 
also contribute to AD pathology in other subgroups [21, 22]. 
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the polymerization of NFT, including A42 [13], caspase 
activation [23] or decrease in insulin-like growth factor I 
(IGF-I) signaling [24]. 
  Several age-related disorders that contribute to AD pa-
thology have been described, in particular dysfunctions in 
antioxidant responses and mitochondrial homeostasis [25-
27]. Higher oxidative damage in both peripheral and CNS 
tissues has been documented in AD patients, even at early 
stages of the disease [28]. Other abnormalities associated 
with AD include impairment in DNA repair [29], deregula-
tion of calcium homeostasis and altered immune responses 
[30], as well as evidence of neuroinflammation [31, 32] and 
cerebrovascular pathology [33]. In many cases, oxidative 
stress is a common denominator and could be linked to un-
derlying genetic hubs shared by these pathways. We recently 
identified an impaired genetic expression network in spo-
radic AD that may coordinate oxidative stress defense 
mechanisms and DNA repair responses [9]. 
  Considerable efforts in defining surrogate biomarkers in 
order to facilitate the diagnosis of AD are underway (re-
viewed in [34]). The most robust AD biomarker at this time 
is the combined decrease in A42 and increase in phosphory-
lated tau levels in cerebrospinal fluid (CSF). Unfortunately, 
this combination of biomarkers is not useful for the predic-
tion of earlier stages without clinically defined dementia, 
such as mild cognitive impairment (MCI) [35]. Moreover, 
lumbar puncture for CSF examination is relatively invasive, 
and unsuitable for mass screening of the aging population. 
Readily accessible biomarkers from a minimally-invasive 
blood (or other peripheral) specimen would greatly facilitate 
the management of this condition [34]. 
  Impairment in miRNA expression or function contributes 
to human diseases and has great potential as disease bio-
markers [36]. Although their modes of action are complex, 
miRNAs generally act as post-transcriptional repressors of 
their target gene and/or protein [37, 38]. Major implications 
for miRNAs in the etiological pathways and associated risk 
factors may be anticipated in AD. Characterization of under-
lying etiopathogenetic pathways related to miRNA dysfunc-
tion holds promise for the diagnosis, prognosis and man-
agement of AD and other neurological diseases. We pro-
vided evidence of augmented miRNA expression in periph-
eral blood mononuclear cells (PBMC) in sporadic AD, 
which may shed new light on the pathogenesis of AD and 
provide accessible blood-based diagnostic and prognostic 
biomarkers for this condition [39]. 
THE ROLES OF MICRORNA IN THE CENTRAL 
NERVOUS SYSTEM 
1. Small Noncoding MicroRNAs 
  The unprecedented discovery of small noncoding miR-
NAs and their implications for virtually all biological func-
tions [40-42] is still in early stages of research with at least 
1000 or more miRNAs expected to be identified in the hu-
man genome [43]. At present, 706 human miRNA genes 
have been registered in stem-loop form in the web-database, 
miRBase (Sanger Institute, version 13.0) [44]. With the ex-
ception of the founding let-7 family of microRNAs in mam-
mals [45], their annotation is based on their cloning chronol-
ogy, with family members distinguished in alphabetical 
and/or numerical order [46]. 
  The great majority of miRNA genes are transcribed by 
RNA polymerase II under the regulation of type II promot-
ers, with a few exceptions being constitutively expressed by 
type III promoters [47]. MicroRNAs are found in various 
inter- and intragenic locations, and at least 42% are esti-
mated to be expressed in clusters [48]. The pri-miRNA tran-
scripts are cleaved by the endonuclease Drosha complex into 
hairpin secondary structures called pre-miRNAs in the nu-
cleus, and then exported into the cytoplasm where they are 
cleaved by the endonuclease Dicer into 18 to 22 nucleotide 
long mature miRNAs [49]. MicroRNA expression is regu-
lated not only at their promoter, but also at post-transcrip- 
tional levels of processing [50]. In fact, Dicer is localized to 
the somatodendritic compartment in neurons and glia [51] 
and is activated to process pre-miRNA precursors following 
synaptic signaling [52]. 
  The mature miRNAs are then assembled into RNA-
induced silencing complexes (RISC) and bind to partially 
complementary sites mostly within the 3' untranslated region 
(UTR) of target mRNAs (reviewed in [49, 53, 54-56]). 
Regulatory subunits within the RISC complex and/or present 
on the mRNAs (i.e. cytoplasmic ribonucleoprotein com-
plexes, mRNPs) play decisive roles in miRNA-mRNA local-
ization, miRNA responsiveness to cellular signaling and 
mode of action [37, 56, 57]. The miRNP-mRNA complex 
may be directed to polyribosomes in sub-cellular compart-
ments, where miRNA regulate translation. Alternatively, the 
complex accumulates in foci termed P-bodies and/or gran-
ules for mRNA storage or degradation [53, 56]. While the 
various regulatory factors and signaling effectors associated 
with miRNA regulation are not fully understood, an example 
of a stress responsive mechanism to redirect stored mRNA in 
P-bodies back into translation has been described for the 
RNA-binding protein, HuR [58]. Similar mechanisms of 
reversal in miRNA-mediated repressions are expected within 
miRNP-mRNA complexes in diverse brain and synaptic 
functions [56]. 
  The principles of target recognition for miRNA:mRNA 
duplex formation are based on the complementarity of an 
eight nucleotide seed region (reviewed in [59-61]). Various 
algorithms are now available to predict major evolutionarily 
conserved targets in 3'UTR for over 60% of mRNAs [61]. 
One single miRNA has hundreds of potential gene targets, 
whereas dozens or more microRNA response elements 
(MRE) are predicted in the 3'UTR of individual transcripts. 
However, mechanisms of alternative splicing [62] and 
3'UTR cleavage [63] have evolved to alter miRNA regula-
tion in specific cellular context. Improvement of target pre-
diction by algorithms are expected to eventually take into 
account such variables as cell-specific splicing, MRE acces-
sibility within mRNA secondary structures [64], the presence 
of protein binding sites [65], and perhaps RNA editing [66, 
67]. In fact, miRNA editing occurs at a high frequency in the 
brain and may serve to silence miRNAs [68]. Alternatively, 
miRNA editing may also reinforce and stabilize miR:mRNA 
duplex in order to favor target silencing by mRNA cleavage 
[69]. 
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  Multiple miRNAs are involved in regulating either a sin-
gle gene or sets of genes in common and divergent genetic 
networks. Despite the extreme level of complexity in 
miRNA regulatory networks, one approach to facilitate the 
identification of biological functions is to integrate genomic 
(i.e. mRNA, miRNA) and proteomic expression data with 
miRNA target predictions in the same cellular context. This 
approach successfully identified target predictions from 
various algorithms in various species and experimental sys-
tems, some of which are validated in cell-based functional 
assays (Table 1A, B). Eventually, bioinformatics tools will 
assist in the delineation of regulatory networks and feedback 
loops, by integrating signaling and transcription factors and 
identifying the presence of regulatory elements and links 
with other miRNAs. Despite the arduous task ahead, key 
miRNAs and their regulatory feedback loops have been iden-
tified with specific CNS functions and neurological disorders 
(Table 1A, B). 
2. The Identification of MicroRNAs in the CNS 
  The role of miRNAs in neuronal development and func-
tion was first elucidated in Caenorhabditis elegans [110]. 
The importance of miRNAs in CNS functions and disease is 
now well recognized (reviewed in [111-122]). Initially, the 
implication of miRNAs in mammalian CNS was determined 
by miRNA expression profiling [117, 123]. Among the first 
hundred miRNAs cloned, miR-7, -9/9*, -124a, -124b, -125a, 
-125b, -128, -132, -135, -137, -139, -153, -149, -183, and 
miR-219 were reported to be abundantly expressed in mouse 
Table 1A.  Identification of MicroRNA Associated with the Central Nervous System 
MicroRNA Cell/Tissue Target
1. Functions  Sp.  Ref.
2. 
Down-Regulated  
miR-9, 131  Presenilin 1 knockout  -  Brain development  m  [72] 
miR-130a, 206   Mesenchymal stem cell  TAC1  Neurotransmission  h  [73] 
Up-Regulated  
let-7a/c/e  P19; embryo  -  Neuronal speciation  m  [50] 
miR-7 Vasotocinergic  neuron  -  Neurosecretion  z  [74] 
miR-9-1 Embryo  Fgf  genes  CNS  development  z  [75] 
miR-9a  Sensory organs   Senseless  Sensory neuron  d  [76] 
let-7g, miR-21,  
27a/b, 29a, 138 
SH-SY5Y -  Neurogenesis    [77] 
miR-23 NT2  HES1  Neurogenesis  h  [78] 
miR-26a Hippocampus  MAP2  Dendrite  r  [79] 
miR-30a-5p  Prefrontal Cortex  BDNF  Cortical development & function  h  [80] 
miR-124  P19; neural tube  SCP1  CNS development  c/m  [81] 
miR-124  Neural tube  LAMC1 ITGB1  Neuronal speciation  c  [82] 
miR-124  CAD; N2a  PTBP1  Brain-specific alternative splicing; Neurogenesis  m  [83] 
miR-125b P19  Lin-28  Neurogenesis  m  [84] 
miR-132  PC12; neuron  p250GAP  Neuronal plasticity  r  [85] 
miR-134  Hippocampus  Limk1  Dendrite & synapse  m/r  [86] 
miR-184  Cortical neurons  -  Synaptic plasticity (DNA methylation)  m  [87] 
miR-200 family  Embryo  neuroD, foxg1, lfng, zfhx1  Olfactory neurogenesis  m/z  [88] 
miR-200b  Hippocampus  ZFHX1B  CNS development; TGF-signaling   m  [89] 
miR-204  Choroid plexus  TRPM3  CSF associated  m  [90] 
miR-430 Embryo  -  Brain  morphogenesis  z  [91] 
1. Reported miRNA target’s gene symbol: APP, amyloid precursor protein; BACE1, -site APP cleaving enzyme 1; BDNF, Brain-derived neurotrophic factor; CFH, Complement 
factor H; fgf, fibroblast growth factor; GRIA2, Glutamate receptor subunit; HES1, Hairy and enhancer of split 1; ITGB1, Integrin 1; LAMC1, laminin 1; Limk1, Lim-domain-
containing protein kinase; MAP2, Microtubule -associated protein 2; p250GAP, p250GTPase-activating protein; PITX3, Paired-like homeodomain transcription factor Pitx3; PTBP1, 
Polypyrimidine tract binding protein 1, PTB/hnRNPI; SCP1, Small C-terminal domain phosphatase 1; SLITRK1, Slit and Trk-like 1; TAC1, Tachykinin; TRPM3, Transient receptor 
potential cation channel M3; VSNL1, Visinin-like 1; ZFHX1B, Zinc finger E-box binding homeobox 2, ZEB2. 
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and human adult brains [124]. Several more miRNAs, in-
cluding let-7 family members were shown to co-purify with 
polysomes in neurons [125]. Similar miRNAs were also 
identified in rat and monkey [126]. 
  More refined cellular specificity in their expression was 
reported for astrocytes (miR-23, -26, -29), neurons (miR-
124, -128) [127], and hippocampal neurons (let-7 family) 
[50]. Cellular speciation associated with orthologue miRNAs 
was also reported in zebra fish for neuronal precursors (miR-
92b), mature neurons (miR-124, -181, -222), motor neurons 
(miR-218a) and dendrites (miR-134) [128]. Likewise, in rat 
hippocampal neurons, miRNAs have been sub-localized 
Table 1B.  Identification of MicroRNA Associated with Neurological Diseases 
MicroRNA Cell/Tissue Target
1. Associated  Disease  Sp.  Ref.
2 
Down-Regulated   
miR-8   Adult flies  Atrophin  Behavorial defect model  d  [70] 
let-7  Larval  APP-like  AD model system  c.e.  [92] 
miR-106a  HEK-293  APP  AD functional assay  h  [93] 
miR-106b Cortex  APP  AD  h  [94] 
miR-298, 328  Brain  BACE1  AD model system  m  [95] 
miR-29a/b-1 Cortex  BACE1  AD  h  [96] 
miR-107  Temporal cortex  BACE1  AD, MCI  h  [97] 
let-7i, miR-9, 15a, 26b, 93, 181c, 210  Cortex  -  AD  h  [96] 
miR-124b Hippocampus  -  AD  h  [98] 
miR-9, 132, 146b, 210, 212, 425  Hippocampus & FG    AD  h  [99] 
miR-15b, 146b, 181c, 338  CSF  -  AD  h  [99] 
miR-9/, miR9*  Cortex  REST/CoREST  HD  h  [100] 
miR-29b; 124a  Cortex  -  HD  h  [100] 
miR-132 Cortex  p250GAP  HD  h  [101] 
miR-10b; 132, 495  Brainstem  -  PD  m  [102] 
miR-133b dopaminergic  neuron  PITX3  PD  h/m  [103] 
miR-338-3p; 337-3p  Brain  -  Prion disease  m  [104] 
miR-26b, 29b  Prefrontal cortex  -  Schizophrenia  h  [105] 
miR-9, 124a, 125b  Spinal cord  -  Spina bifida model  r  [71] 
Up-Regulated   
let-7c, miR-99a, 125b-2, 155, 802  Fetal brain  -  DS  h  [106] 
miR-197, 320, 511, 520h, 516-3  Cortex    AD  h  [96] 
miR-9, 125b, 128, 130, 145  Hippocampus  -  AD/ ROS generating metals  h  [98, 107] 
miR-146a  Hippocampus & cortex  CFH  AD/ A & ROS inducible   h  [108] 
miR-27a, 34a, 92, 145, 381, 422a, 423  Hippocampus & FG  -  AD  h  [99] 
let-7f, miR-30, 125a, 197, 371, 517, 520a  CSF    AD  h  [99] 
let-7f, miR-34a, 155, 181b, 200a, 371, 517*  BMC  -  AD  h  [39] 
miR-29a, 330  Cortex  -  HD  h  [101] 
miR-218; 132  Cortex    HD  h  [100] 
let-7b, miR-146a; 128; 139-5p;320; 328; 342-3p   Brain   Prion  disease  m  [104] 
miR-106b Prefrontal  cortex  -  Schizophrenia  h  [105] 
miR-181b Temporal  cortex  VSNL1/GRIA2  Schizophrenia  h  [109] 158    Current Genomics, 2009, Vol. 10, No. 3  Maes et al. 
within soma and dendrite compartments, including miR-124 
and miR-26a respectively [79]. In human prefrontal cortex, 
miR-30a was shown to be enriched in pyramidal neurons 
[80]. A detailed comparison of miRNA expression profiles 
in mouse and zebra fish CNS revealed species differences 
[129]. Eventually, a tissue and sub-cellular cartography of 
microRNA levels in human CNS should contribute to a more 
complete understanding of their functions. 
  A detailed functional analysis for a human miRNA was 
accomplished for the predominant brain miRNA, miR-124 
[130]. Direct evidence of a role for miR-124 was derived 
from its over-expression in HeLa cells, which shifted the 
gene expression pattern to that of a neuron [131]. Expression 
of miR-124a was shown to be under the negative control of 
the transcriptional repressor, REST (RE1 silencing transcrip-
tion factor), a regulator of neuronal differentiation [132]. In 
turn, miR-124 targets the REST-binding anti-neural factor, 
SCP1 (Small C-terminal domain phosphatase 1), and rein-
forces the induction of neurogenesis [81]. Its constant ex-
pression also maintains neuronal speciation [82], in part by 
targeting the polypyrimidine tract binding protein 1 (PTBP1/ 
hnRNPI), a repressor of alternative splicing expressed in 
non-neuronal cells [83]. Thus, miR-124 may act at different 
levels of gene regulation for neuronal speciation, involving 
complex regulatory and splicing mechanisms and negative 
feedback loops [133]. 
  Another key miRNA under the regulation of REST is 
miR-9 [134]. This miRNA is reported to have several func-
tions depending on its cellular context, such as in CNS de-
velopment [71], midbrain-hindbrain boundary formation 
[75], or in oxidative stress responses [107]. In Drosophila, 
miR-9 regulates the transcription factor Senseless in the de-
velopment of the peripheral nervous system [76]. MicroRNA 
miR-9 is also required for brain functions, as suggested in 
PSEN1 null mice, where its decrease is associated with se-
vere brain defects [72]. The loss of PSEN1 impacts memory, 
synaptic plasticity and induces neurodegenerative changes 
[135, 136]. 
  Also noteworthy is the let-7 family which is strongly 
expressed in brain and neuronal stem cells [50]. The evolu-
tionarily conserved let-7 family members are highly edited 
[69], and the processing of pri-let-7 into active mature miR-
NAs is tightly regulated in the brain [50]. One possible post-
transcriptional regulation is by the RNA binding protein, 
Lin28 [137], which binds to the pri-let-7 precursor in order 
to inhibit its processing by Drosha [138, 139]. The expres-
sion of miR-125 during neurogenesis suppresses Lin28 [84] 
and together with let-7 further represses Lin28 in an 
autoregulatory circuit [140]. Moreover, let-7 directly regu-
lates Dicer and may have a global regulatory control on 
miRNA functions [141]. At this time, no specific CNS func-
tions are described for the let-7 family members in humans; 
however, their roles in differentiation and as tumor suppres-
sors have been demonstrated [142]. 
3. MicroRNA Associated with Neurological Diseases 
  The relationship between microRNA dysfunctions and 
neurological diseases is perhaps best illustrated with fragile 
X mental retardation. In these patients, the absence of Fragile  
 
X mental retardation 1 protein (FMRP) impairs Dicer and 
RISC functions required for miRNA-mediated synaptic plas-
ticity and dendritic development [143]. Experimentally, al-
tering miRNA processing by the inactivation of Dicer in 
Drosophila also prevents dendritic development [144] and 
enhances polyglutamine and tau-induced neurodegeneration 
[145]. Likewise, inactivation of Dicer in the CNS of mice 
impairs dendrite formation, neuronal survival, and gradually 
leads to neurodegeneration [146-148]. 
  Dysfunction in RISC complex formation also occurs in 
the pathology of Huntington disease (HD). The interaction of 
the HD protein with one of the RISC subunit Argonaute-2 is 
impaired in HD, which prevents the formation of P-bodies 
[149]. Moreover, impairment in HD protein regulation of 
REST results in the repression of miRNA expression in HD 
brains, in particular the down-regulation of miR-132 affect-
ing neurite outgrowth [101] and the down regulation of miR-
124a and miR-9/9* affecting a double negative feedback 
loop regulation of REST with miR-9 [100]. This suggests 
that the down-regulation of key miRNAs regulated by REST 
predisposes to neurodegenerative disorders. 
  The association of miRNA with another polyglutamine 
disease, dentatorubral-pallidoluysian atrophy, is suggested in 
Drosophila; mutation in miR-8 (orthologue miR-200a/b and 
miR-429) causes apoptosis in the brain and behavioral de-
fects, along with an increase histone deacetylase (HDAC) 
activity [70]. HDAC inhibitors have protective effects in the 
treatment of stroke, AD, amyotrophic lateral sclerosis (ALS) 
and HD [150] and alter both gene and miRNA expression 
[151]. This suggests that miRNAs such as the miR-200 fam-
ily could be involved in HDAC deregulation in neurological 
diseases. 
  Interestingly, miR-200a was found to be increased in AD 
brain [99] and peripheral blood mononuclear cells (PBMC) 
[39]; however, its function in AD pathology is not yet estab-
lished. A specific role has been described for miR-200b in 
the regulation of a ZFH-1 repressor (ZFHX1B), involved in 
the regulation of E-cadherin expression in mouse brain [89]. 
Importantly, E-cadherin is a substrate of PSEN1, which is 
related to diverse brain functions and synaptic plasticity 
[152]. The miR-200 family is also involved in functions of 
the olfactory system [88], pathways implicated in neurode-
generative conditions such as AD and Parkinson disease 
(PD) [153]. 
  In PD, miR-133b is deficient in midbrain dopaminergic 
neurons, and may be related to an impaired feedback loop 
with the Paired-like homeodomain transcription factor, 
PITX3 [103]. Polymorphisms in PITX3 are associated with 
PD [154], and perhaps this impairs its capacity to induce 
miR-133b expression. In another study, a polymorphism 
associated with PD modified the microRNA binding site of 
miR-433 in the transcript of fibroblast growth factor 20 
(FGF20), resulting in increased alpha-synuclein expression 
[155]. Other polymorphisms have been associated with neu-
rological disease, such as in the noncoding genes of miR-198 
and miR-206 associated with schizophrenia [156], as well   
as in the binding site of miR-189 in Slit and Trk-like 1 
(SLITRK1) mRNA associated with Tourette syndrome 
[157]. MicroRNA  Current Genomics, 2009, Vol. 10, No. 3    159 
  Genetic defects such as trisomy 21 (Down syndrome, 
DS) lead to neurodegenerative pathology consistent with 
AD. In particular, extra copies of APP [158] and Dyrk1a 
[159] genes on chromosome 21 contribute, respectively, to 
SP and NFT, lesions typical of AD-affected brain. Moreover, 
extra copies of let-7c, miR-99a, -125b-2, -155, and miR-802 
on chromosome 21 are also over-expressed in DS patients 
[106]. Interestingly, increased Dyrk1a levels may augment 
REST expression [160], suggesting that other microRNAs 
under the regulation of REST could be affected. 
MicroRNAS AND ALZHEIMER DISEASE PATH-
WAYS 
1. MicroRNA Profiling in Alzheimer Disease 
  The entorhinal cortex-hippocampus system, concerned 
with memory functions, is among the first regions of the 
brain to be affected by AD pathology [161, 162]. In an initial 
expression profiling of the 13 most abundant brain miRNAs 
mentioned above [124], Lukiw [98] reported the up-
regulation of miR-9, miR-125b and miR-128 in AD affected 
hippocampus (Table 1B). Later, 328 miRNA were profiled 
in the cortex of sporadic AD, showing both up- and down-
regulation in miRNAs [96]. Among over 400 miRNAs pro-
filed, several up-regulated miRNA were reported in AD-
affected hippocampus and medial frontal gyrus, cerebellum 
and CSF [99]. Likewise, we detected mostly an up-
regulation of miRNA expression in PBMC of sporadic AD 
as compared to aged-matched normal elderly control subjects 
[39]. 
  The up-regulation of miR-125b and down-regulation of 
miR-9 and miR-210 have been consistently reported in dif-
ferent studies on miRNA expression profiling of AD-
affected brain (Table 2). The deregulation of miR-125b and 
miR-9 in AD is particularly interesting because, as described 
above, these key miRNAs are involved in brain development 
and function as well as in neurological diseases such as DS 
and HD. The up-regulation of miR-197 and down-regulation 
of miR-15, -146b, -181c, and miR-338 are commonly altered 
in AD brain parenchyma and CSF. 
  MicroRNAs similarly expressed in both AD-affected 
brain and PBMC are identified (Table 2; Fig. 1), including 
the up-regulation of miR-34a, miR-200a and miR-520h, as 
well as the up-regulation let-7f, miR-371 and miR-517/517* 
observed in the CSF and PBMC of AD patients. Of note, 
miR-520h is reported to be highly up-regulated in AD brain 
[96], and its increase in Alzheimer PBMC suggests it may 
have a major role in the systemic manifestations of the dis-
ease. Systemic dysfunction is also indicated by the up-
regulation of miR-34a and miR-200a in AD cortex and 
PBMC. 
  We suggest here that the systemic increase in specific 
miRNAs may suppress various cellular functions in AD, 
such as redox defenses or DNA repair mechanisms, by tar-
geting mRNA and/or protein species in brain and peripheral 
tissues (Fig. 1). Indeed, gene expression studies in AD have 
shown substantial down-regulation of various mRNA species 
in brain [164], PBMC [163] and lymphocytes [165] relative 
to non-demented controls. Likewise, impairment in protein 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Up-regulated microRNA in peripheral blood mononuclear cells (PBMC) of sporadic Alzheimer disease (AD) patients. MicroRNAs 
are small noncoding RNA which generally act as post-transcriptional repressors of gene and/or protein expression. Their common up-
regulation in AD brain, cerebrospinal fluid (CSF) and PBMC as well as in other neurological disorders and aging model systems is shown, 
with implications for oxidative stress, DNA damage and mitochondrial dysfunction. Down-regulated genes in Alzheimer PBMC [163] which 
may be repressed by these miRNAs were identified using target predictions from miRanda algorithm [44]. Major functional categories which 
may be theoretically repressed in AD-affected PBMC are indicated. 160    Current Genomics, 2009, Vol. 10, No. 3  Maes et al. 
synthesis is known to occur in AD [166] leading to dimin-
ished protein levels in the CSF [167] and plasma [168] of 
these patients. 
  For example, the up-regulation of peripheral miRNAs in 
AD could contribute to the diminished plasma proteins re-
ported to be predictive biomarkers for AD [168], such as 
chemokine-7 (let-7f, miR-181b) and interleukin-1 (miR-
181b, -200a). Moreover, in our genomics work on Alzheimer 
PBMC, we observed on one hand a significant number of 
down-regulated genes [163], while on the other, only up-
regulation of miRNAs was detected [39]. Interestingly, pre-
dicted targets for up-regulated miRNAs correlated with 
down-regulated genes in functional categories of Synapse 
Activity, Transcription, and Injury/Redox Homeostasis and 
DNA Damage (Fig. 1). This suggests that the systemic up-
regulation of miRNAs in AD may contribute not only to im-
paired redox homeostasis and DNA repair mechanisms, but 
also reflect homologous CNS synaptic dysfunction occurring 
in AD brains. Importantly, this supports the notion that pe-
ripheral miRNA, gene and protein expressions may serve as 
diagnostic and prognostic biomarkers, and possibly provide 
leads to the development of new therapeutic interventions. 
2. MicroRNA Associated with AD Etiopathogenesis 
  Although disorders of APP cleavage have been impli-
cated in the etiopathogenesis of AD, experience with Down 
syndrome (DS) raised the possibility that hyper-expression 
of the APP gene may contribute to A production in some 
forms of sporadic AD. In this respect, there is a long list of 
predicted miRNAs (i.e. from DIANA-microT, miRanda, 
TargetScanS algorithms) that may target the 3'UTR of APP, 
including let-7i, miR-15, -26, -29, -93, -101, -106, and miR-
181 which are reportedly down-regulated in AD brain [96, 
99]. 
 In  C. elegans, the APP-like orthologue is targeted by the 
single let-7 supporting the notion that the let-7 family of 
miRNAs in humans could be involved in the regulation of 
APP [92], e.g. let-7i which is reported to decrease in AD 
brain [96]. In humans, the over-expression of miR-106a/b 
was shown to reduce APP protein levels in kidney cells [93, 
94]. This validates this target prediction for APP, and is con-
sistent with the fact that miR-106a/b is down-regulated in 
AD-affected brain [94]. The down-regulation of miR-106a/b 
(Fig. 2), perhaps with other down-regulated miRNAs (let-7i, 
Table 2.   Similarly Altered Patterns of MicroRNA Expression in Alzheimer Disease and Aging Model Systems 
Alzheimer Disease Affected Tissue 
MicroRNA
1. 
Cortex Hippocampus  Cerebellum    CSF  PBMC 
Aging Model  Reference 
Down-Regulated  
let-7i          [96,169] 
miR-9            [99,  96] 
miR-15          [99,  96] 
miR-146b           [99] 
miR-181c          [99,  96] 
miR-210            [99,  96] 
miR-338          [99,  96] 
miR-451           [99,169] 
Up-Regulated  
let-7f           [99, 39, 181] 
miR-30d           [99,  169] 
miR-34a            [39, 99, 169, 170] 
miR-125b            [99,  98] 
miR-197          [99,  96] 
miR-200a           [99,  39] 
miR-371            [99,  39] 
miR-517            [99,  39] 
miR-520h           [96,  39] 
1. MicroRNAs that show similar expression trends in the various AD tissues and aging models are reported. Distinct sets of miRNAs expressed in the different systems are not 
shown. MicroRNA  Current Genomics, 2009, Vol. 10, No. 3    161 
miR-15, -26, -29, -93 -101), may favor higher APP levels in 
AD brains. 
 The  A cleavage product of APP may then arise from the 
increase in BACE1 and PSEN1 levels (Fig. 2). Of note, 
BACE1 and APP appear to be targeted by similar sets of 
miRNAs, including miR-9, -15, -27, -29, and miR-101. 
These miRNAs may therefore facilitate increases in both 
APP and BACE1 in AD brain. In fact, over-expression of 
miR-29a/b-1 reduces APP and BACE1 levels in kidney cells 
[96]. Another miRNA that targets BACE1 and is down-
regulated in early AD and MCI-affected cortex is miR-107 
[97]. In this latter example, the identification of miRNA 
binding sites in BACE1 was determined without stringent 
cross-genome conservations using the algorithm rna22 (as 
opposed to miRanda or TargetScan used above). 
  Mutations in PSEN1 and PSEN2 account for the majority 
of FAD cases and the products of these genes have been im-
plicated in sporadic AD as well [135]. In PSEN1 knock-out 
mice, Notch signaling and transcriptional networks associ-
ated with miR-9 expression decrease and reflect to some 
extent the loss-of-function PSEN1 mutations associated with 
FAD pathology [72]. In the pathogenesis of sporadic AD, 
augmented PSEN1 mRNA levels [171, 172] may foster A 
production by sequential cleavage of APP (Fig. 2). Interest-
ingly, miR-9 is predicted to target PSEN1, suggesting that 
the up-regulation of PSEN1 could be associated with the 
decline in miR-9 levels in AD. 
  The down-regulation of miR-9 and miR-29 is, however, 
not specific to AD (Table 1B) as these miRNA species are 
also diminished in the brains of individuals with schizophre-
nia [105] and HD [100]. Conceivably, aberrant profiles of 
neural miRNA expression shared by various neurological 
disorders may give rise to common patterns of cellular dys-
function in these conditions. Moreover, deregulations in 
gene and protein expression may also include other mecha-
nisms, such as long noncoding antisense BACE1 transcript 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). A simplified scheme of etiopathogenetic pathways associated with microRNA dyregulation in sporadic Alzheimer disease (AD). 
Sporadic AD may be characterized by the increase in hallmark genes (i.e. APP, BACE1, PSEN1) which contribute to amyloid beta (A) 
production by sequential cleavage of APP. Altered miRNAs reported in AD brain which target these genes (as predicted by miRanda and 
TargetScan algorithms and validated in cell-based assays) are shown [93, 94, 96, 97, 108]. The REST complex negatively regulates the ex-
pression of miR-9, miR-29 and miR-124 [134]. The negative feedback loop by miR-9 which suppresses REST is impaired in AD and other 
neurological diseases. Familial AD (FAD) PSEN1 loss-of-function mutations are recapitulated by PSEN1 knock-out in mouse [72], leading 
to the decrease in miR-9 akin to that observed in sporadic AD brain. Oxidative stress and DNA damage, generated in part by elevations in 
amyloid beta (A), iron and reactive oxygen species, induce miRNA expression as exemplified by miR-34a and miR-146a. The stress re-
sponsive transcription factor p53, which may increase in AD by A transactivation [173], may further transactivate miR-34a [174]. Stress-
mediated neuroinflammatory responses are represented by nuclear factor-kappa B (NF-B) which transactivates the expression of miR-146a 
[108] and BACE1 [175]. Barred lines denote post-transcriptional repression of target genes and crossed lines denote de-repression associated 
with the down-regulation of miRNAs. 162    Current Genomics, 2009, Vol. 10, No. 3  Maes et al. 
which increases BACE1 expression in AD [176]. Thus, al-
terations in noncoding RNA expression which affect CNS 
functions or are associated with neurological diseases are not 
limited to miRNA species (review in [177]). 
3. MicroRNA Associated with Oxidative Stress and AD 
Risk Factors 
  Aging remains the most robust risk factor thus far identi-
fied for sporadic AD and other human neurodegenerative 
conditions. Mechanisms of aging under the regulation of 
miRNAs may contribute to AD pathology, such as those 
identified in various aging model systems, including the up-
regulation of let-7f, miR-30d, -34a, -432, -517 and down-
regulation of let-7i and miR-451 (Table 2). These miRNA 
may reflect intrinsic aging mechanisms in AD [178]. In par-
ticular, there is a systemic increase in miR-34a in AD brain 
[99] and PBMC [39], as well as in aging mouse liver [169] 
and C. elegans [170]. The up-regulation miR-34a may partly 
result from DNA damage [179], which accumulates during 
aging and to an even greater extent in AD [180]. Likewise, 
the increase in let-7f may be related to DNA damage and 
cellular senescence, as it is up-regulated in replicatively se-
nescent cells [181] and Alzheimer CSF [99] and PBMC [39]. 
Replicative senescence correlates with gradual telomere 
shortening and DNA damage, largely due to the high oxygen 
tension (20% O2) that exists in culture [182]. Importantly, 
the up-regulation of let-7 in DS and miR-34a in AD (Table 
1B) also suggests that mechanisms of aging and senescence, 
perhaps related to DNA damage responses, are involved in 
degenerative processes within the brain. 
  Oxidative DNA damage is an early and systemic event in 
the pathophysiology of AD [183, 184]. In our studies on 
miRNA and gene expression in AD PBMC, we observed 
impaired DNA repair and antioxidant gene responses, which 
correlate with the up-regulation of miR-181b, -200a, -517* 
and miR-520h, and may possibly repress DNA repair and 
oxidative stress response mechanisms [39]. Oxidative dam-
age in AD tissues also accrues from a gradual decline in an-
tioxidant defenses and increasing neural levels of redox-
active transition metals and other pro-oxidant species [26]. 
AD-associated miRNAs activated by stress-inducing agents, 
such as aluminum and iron sulfates, include miR-9, miR-
125b and miR-128 [98, 107]. 
  Another major source of reactive oxygen species in AD 
stems from infidelity of electron transport in dysfunctional 
mitochondria [26] which can be recapitulated using arsenic 
and other stressors [185, 186]. Similar to miRNA deregula-
tion in AD, human lymphoblastoid cells up-regulate miR-
34a and down-regulate miR-210 following arsenic treatment, 
as well as up-regulate miR-125b, -130, -145 and miR-181b 
under conditions of folate deficiency [187]. Folate deficiency 
may cause cognitive impairment and decrease DNA repair 
mechanisms with age [188, 189]. Analogous patterns of al-
tered miRNA expression in AD suggest that similar mito-
chondrial and ROS mediated dysfuntions are associated with 
these miRNAs. Interestingly, miR-181b is up-regulated in 
schizophrenia-affected brains where mitochondrial dysfunc-
tion has been documented [190], and may warrant further 
investigation in AD brain in light of its up-regulation in AD 
PBMC. 
  Stress-responsive miRNAs that are implicated in cardiac 
hypertrophy [191] and vascular disease [192] may similarly 
participate in the vascular pathology of AD, pure vascular 
dementia and mixed dementia [193, 194]. In this context, 
prime examples of the latter include the up-regulation of 
miR-27a/b [99], miR-125b [98] and down-regulation of 
miR-93 [96], as observed in AD brain. It may be of particu-
lar interest to determine whether the over-expression of miR-
155 in DS brain is associated with macrophage-related in-
flammation [195]. Also characteristic of AD-affected neural 
tissues are neuroinflammatory responses activated by the 
transcription factor, nuclear factor-kappa B (NF-B), which 
induces the expression of miR-146a [108]. The expression of 
miR-146a was also shown to be induced by ROS-generating 
agents such as hydrogen peroxide and A42. Taken together, 
these data indicate that up-regulation of miR-27a/b, -125b, -
146a and down-regulation of miR-93 may contribute to the 
stress-related vascular and inflammatory components of AD 
pathology. 
PERSPECTIVE 
  Deregulation of miRNAs in the CNS may impact a wide 
range of cellular functions that are not limited to the etiopa-
thogenesis of AD. The identification of homologous patterns 
of miRNA expression among diverse neurological conditions 
may denote common pathways of neuronal dysfunction and 
degeneration. For example, the up-regulation of miR-181b in 
schizophrenia, or let-7 and miR-125b in DS, are also ob-
served in sporadic AD and may denote common mechanisms 
of disease (Table 1B). If confirmed, single pharmaceuticals 
targeting specific miRNA regulatory pathways may prove 
effective in the treatment of multiple neurological afflictions. 
The probable decline of miR-9 in AD suggests that its target 
REST may induce the repression of other neuronal genes and 
miRNAs (i.e. miR-29a/b, -124, and -132) as reported in the 
hereditary neurodegenerative disorder, HD [100]. 
  Discrepancies in miRNA expression data in AD are not 
unexpected and further studies will be required to determine 
whether disparate data are due to genetic or demographic 
determinants. Genetic polymorphisms in miRNA sequences, 
in their promoter regions or in the 3'UTR binding sites of 
their targets may alter miRNA expression and function. Dif-
ferent genetic backgrounds among familial or sporadic AD 
patients could well be reflected by specific miRNA expres-
sion signatures. For example, we found more robust up-
regulation of miR-181b and miR-371 in Alzheimer PBMC 
relative to control subjects in the APOE4-positive stratum 
[39]. This suggests that a higher expression of specific miR-
NAs in APOE4-positive carriers may contribute to earlier 
onset of the disease as observed in these patients. It also 
raises the possibility that specific PBMC gene and miRNA 
expression signatures may distinguish the various at-risk 
genetic backgrounds associated with AD. 
  To understand more thoroughly the role of miRNAs in 
diseases of the CNS, target predictions will need to be re-
fined taking into account variables such as RNA editing, 
splicing and secondary structures. The elucidation of 
miRNA’s role in AD pathology is based on their expression 
in affected brain and on predictions of their targets, the latter 
being validated in cell-based functional assays. The fine tun-MicroRNA  Current Genomics, 2009, Vol. 10, No. 3    163 
ing of a gene (or protein) level is not limited to one miRNA 
[196], and the net effect on a given target shared by con-
comitantly down- and up-regulated miRNAs remains un-
clear. The identification of up-regulated miRNAs having 
targets which nonetheless increase in the same AD brain 
tissue (i.e. APP, BACE1) may suggest loss-of-function either 
by genetic polymorphisms or miRNA editing. 
  At present, the impact of miRNA deregulation in com-
plex regulatory networks within the brain is not known, nor 
how sets of miRNAs interact in the regulation of shared tar-
gets. To delineate further salient cause-effect relationships in 
these regulatory pathways, more in-depth characterization of 
the promoter elements and various transcription factors and 
repressors (i.e. REST, A, NF-B, p53, etc.) which alter 
miRNA expression is paramount. It will also be necessary to 
determine which sets of miRNAs are affected in different 
genetic backgrounds and regions of the CNS, and how they 
integrate within the various regulatory loops and diverging 
networks implicated in AD and other neurological diseases. 
  Future studies employing relevant transgenic mouse 
models should facilitate the elucidation of the beneficial or 
detrimental effects of specific sets of miRNA in AD pathol-
ogy. As systemic oxidative damage is characteristic of the 
AD phenotype, the silencing of specific up-regulated miR-
NAs (i.e. miR-34a, -181b, -520h) which may impair stress 
defense and repair mechanisms could reduce ROS levels and 
related cellular dysfunctions in AD. Conceivably, specific 
sets of miRNAs will one day be used as a disease-modifying 
treatment of AD [197]. In the inexorable progress towards 
personalized medicine, the design of therapeutic miRNA 
regimens to modify diseased gene expression profiles may 
be informed by highly-individualized genomic signatures. It 
is also conceivable that miRNAs may provide minimally-
invasive, blood-based biomarkers to facilitate early diagnosis 
and prognosis of MCI and AD and serve as surrogate indices 
of successful therapeutic interventions in these and other 
human CNS afflictions [198]. 
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ABBREVIATIONS 
A =  Amyloid  beta 
AD =  Alzheimer  disease 
c =  Chick 
c.e. =  Caenorhabditis  elegans 
CNS =  Central  nervous  system 
CSF =  Cerebrospinal  fluid 
d =  Drosophila  melanogaster 
DS =  Down  syndrome 
FAD  =  Familial Alzheimer disease 
FG =  Frontal  gyrus 
h =  Human 
m =  Mouse 
miRNA = MicroRNA 
miRNP = MicroRNA-cytoplasmic  ribonucleoprotein 
complex 
HD =  Huntington  disease 
MCI =  Mild  cognitive  impairment 
MRE =  MicroRNA  response  element 
NFT =  Neurofibrillary  tangle 
PBMC  =  Peripheral blood mononuclear cell 
PD =  Parkinson  disease 
r =  Rat 
RISC  =  RNA-induced silencing complex 
SP =  Senile  plaque 
TS =  Tourette  syndrome 
UTR =  Untranslated  region 
z =  Zebrafish 
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